Trastuzumab Deruxtecan
DS8201-793
Phase 3 small_molecule active
Quick answer
Trastuzumab Deruxtecan for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Daiichi Sankyo with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo
- Indication
- Non-small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active